Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART
Condition: HIV InfectionsInterventions: Biological: LC002 standard vaccination; Biological: LC002 high-dose vaccination; Biological: LC002 placebo vaccinationSponsors: National Institute of Allergy and Infectious Diseases (NIAID); AIDS Clinical Trials GroupCompleted - verified March 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Highly Active Antiretroviral Therapy | Infectious Diseases | Research | Vaccines